A Single Centre, Two Treatment, Two Period, Two Sequence, Randomized Crossover Steady-state Relative Bioavailability Study of Naproxen in Two Tablet Formulations Given Twice Daily (PN 400 Tablets Containing 500mg of Naproxen Plus 20mg of Esomeprazole Versus Naprosyn Containing Naproxen 500mg).

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Feb 2010

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Esomeprazole/naproxen (Primary) ; Naproxen
Indications Ankylosing spondylitis; Musculoskeletal pain; Osteoarthritis; Rheumatoid arthritis
Focus Pharmacokinetics
Sponsors AstraZeneca

Most Recent Events

20 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
16 Oct 2009 New trial record

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight